Aspirin and Heparin Combination Significantly Improves Live Birth Rates in Women with Recurrent Pregnancy Loss
• A Kobe University-led study reveals that low-dose aspirin or heparin treatment significantly increases live birth rates in women with recurrent pregnancy loss who test positive for specific self-targeting antibodies.
• The research indicates that treatment with aspirin or heparin led to an 87% live birth rate, compared to 50% in untreated women, showcasing a substantial improvement in pregnancy outcomes.
• The study also found that the treatment reduced pregnancy complications from 50% to 6% among live births, highlighting the potential of these drugs to improve maternal and fetal health.
• Women with only the newly discovered antibodies who received the treatment had a 93% live birth rate with no pregnancy complications, suggesting a targeted and highly effective approach.
Atezolizumab and Durvalumab Combination Therapies Not Cost-Effective for ED-SCLC in Japan
• A cost-effectiveness analysis in Japan reveals that atezolizumab and durvalumab, when combined with chemotherapy, are not cost-effective as first-line treatments for extensive-disease small-cell lung cancer (ED-SCLC).
• The incremental cost-effectiveness ratios (ICERs) for atezolizumab and durvalumab combination therapies significantly exceeded the willingness-to-pay threshold of 15 million JPY per quality-adjusted life year (QALY).
• Sensitivity analyses suggest that substantial price reductions for atezolizumab and durvalumab would be necessary to achieve cost-effectiveness, but such reductions are unlikely to be feasible.
• The findings align with previous studies in the USA and China, indicating consistent economic challenges associated with immune checkpoint inhibitor combination treatments for ED-SCLC.
© Copyright 2025. All Rights Reserved by MedPath